Dr. Lynch on the Immuno-Oncology Network at Bristol-Myers Squibb

Thomas Lynch, Jr, MD
Published: Thursday, Jul 26, 2018



Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the Immuno-Oncology (IO) Network at Bristol-Myers Squibb.

The IO Network at Bristol-Myers Squibb is one of the most exciting and successful initiatives that has been done in conjunction with academic sites, says Lynch. According to Lynch, no one company, or no one university is ever going to have all the answers. Physicians need to work together to find and develop new approaches to understanding cancer, as well as how new immunotherapies can be brought to bear in cancer.

Through the IO Network, Lynch says that several outstanding and dynamic sites have been brought together—sites that have both great basic immunology, great clinical immunology, and fantastic cancer care to ask important questions. The IO Network has been a great example of collaboration because of the frank interactions that happen between the scientists at Bristol-Myers Squibb and the scientists at the academic laboratory, says Lynch.
SELECTED
LANGUAGE


Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the Immuno-Oncology (IO) Network at Bristol-Myers Squibb.

The IO Network at Bristol-Myers Squibb is one of the most exciting and successful initiatives that has been done in conjunction with academic sites, says Lynch. According to Lynch, no one company, or no one university is ever going to have all the answers. Physicians need to work together to find and develop new approaches to understanding cancer, as well as how new immunotherapies can be brought to bear in cancer.

Through the IO Network, Lynch says that several outstanding and dynamic sites have been brought together—sites that have both great basic immunology, great clinical immunology, and fantastic cancer care to ask important questions. The IO Network has been a great example of collaboration because of the frank interactions that happen between the scientists at Bristol-Myers Squibb and the scientists at the academic laboratory, says Lynch.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x